| Papua New Guinea (n = 504) | Thailand (n = 999) | |
---|---|---|---|
Placebo arm (n = 257) | Primaquine arm (n = 247) | ||
Gender (male) | 49.8% (128) | 48.6% (120) | 46.2% (462) |
Age (years) | 7.5 (4.9, 10.4) | 7.6 (4.8, 10.4) | 23 (1, 82) |
Bednet usage | 93.4% (240) | 93.1% (230) | 88.8% (888) |
Duration of follow-up (days) | 224 (56, 231) | 224 (42, 229) | 369 (360, 378) |
Proportion of data missing | 12.3% | 10.1% | 8.3% |
Any P. vivax infection by qPCR | 69.6% (179) | 27.9% (69) | 11.9% (119) |
Any P. vivax infection by LM | 54.5% (140) | 21.9% (54) | – |
Number of P. vivax genotypes | 2.2 (0, 12) | 0.7 (0, 7) | 0.3 (0, 11) |
Any P. falciparum infection by qPCR | 37.0% (95) | 34.0% (84) | 2.4% (24) |
Any P. falciparum infection by LM | 23.7% (61) | 27.9% (69) | – |
Number of P. falciparum genotypes | 0.6 (0, 9) | 0.5 (0, 6) | 0.03 (0, 6) |
Any fever | 53.7% (138) | 62.3% (154) | 24.7% (247) |
Any fever with qPCR+ P. vivax | 10.1% (26) | 4.0% (10) | 2.1% (21) |
Any fever with qPCR+ P. falciparum | 9.7% (25) | 16.6% (41) | 0.3% (3) |